Genomma Lab Internacional SAB de CV (LABB) Q3 2026 Earnings Report
0 Followers
MX:LABB Q3 2026 EPS Results
- Actual EPS
- MXN 0.51
- Consensus EPS
- MXN 0.39
- Beat/Miss
- Beat by +MXN 0.12
- One Year Ago EPS
- MXN 0.43
MX:LABB Q3 2026 Revenue Results
- Actual Revenue
- MXN 4.50B
- Expected Revenue
- MXN 4.37B
- Beat/Miss
- Beat by +MXN 125.16M
- YoY Revenue Growth
- +1.27%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/21/2026
- Time
- After Close
- Conference Call
- Wednesday, October 21, 2026
MX:LABB Upcoming Earnings
Genomma Lab Internacional SAB de CV's next earnings date is estimated for February 24, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:LABB Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a cautiously optimistic recovery narrative. Mexico sellout, market share, innovation, Latin America growth, cash flow, liquidity, and debt maturity improvements were significant positives, while the United States remained difficult, margins contracted, working capital increased, Brazil faced tax-reform-related inventory pressure, and part of net income growth came from a nonrecurring foreign exchange gain. Management characterized the quarter as mixed but emphasized that the recovery plan was working and that sellout improvement was underway.
Company Guidance
Management expects a continued gradual recovery during the second half of 2026, Brazil selling to normalize in the first quarter of 2027 once the new tax rules take effect, and The US recovery to be gradual; it expects to sell most of the Mexico inventory in the fourth quarter and the first quarter of 2027, take the cash conversion cycle down to 140 days by the end of the fourth quarter and to approximately 140 days in the fourth quarter, and maintain accounts receivables at the current level going forward. Mexico’s margin is expected to be higher than 20 and to get closer to 27% throughout next year for sure, while overall EBITDA margin will gravitate back to the levels of 23% to 24% Overall, as a corporation.
- Mexico Recovery Continued for a Third Consecutive QuarterMexico net sales declined 2.4%, improving from declines of 4.4% in the second quarter, 8.6% in the first quarter, and 22.1% in the fourth quarter of 2025. Management described this as nearly 20 percentage points of recovery in three quarters, with strong growth in beverages and infant nutrition.
- Mexico Sellout Returned to GrowthMonitored Mexico sellout turned positive and grew 2.7% in July, 7.4% in August, and 8.6% in September, reaching plus 45.8% in the third quarter as stated on the call. Management said the recovery was holding month after month.
- Leading Retailer Sellout AcceleratedAt Genomma's largest client, sellout grew 20% in July, 30% in August, and 22% in September, or 24% for the quarter. Management said this was 41 points above the low point of the second quarter of 2025.
- Suerox Reached a Historic Market-Share HighAt the leading retailer, Suerox sellout improved from minus 25% in late May to plus 81% in August. Value share increased from 6.6% to 12.6%, a historic high and a gain of 6 percentage points in three months.
- Performance Outpaced Several CategoriesThe company said it outperformed its categories in OTC, personal care, and infant nutrition. OTC grew 5.2% against a category decline of 3%, personal care grew 5.8% against a category decline of 9.3%, and infant nutrition grew 7.4% in a flat category. Market share was stable or growing across all Mexico business units.
- Consolidated Net Sales Returned to GrowthConsolidated net sales grew 1.3%, reflecting the ongoing recovery in Mexico and 12.2% growth in Latin America, which more than offset declines of 2.4% in Mexico and 30% in the United States.
- Net Income and Net Margin ExpandedNet profit grew 18.6% to MXN 510 million, while net margin expanded 168 basis points to 11.4%. Management attributed the increase to lower financial expenses and a favorable foreign exchange result.
- Operating Cost Discipline ContinuedProductivity savings reduced SG&A by 1.1% despite higher operating expenses and inflation. Management said operating savings significantly offset inflation.
- Latin America Delivered Double-Digit GrowthLatin America net sales grew 12.2% in Mexican peso terms, and regional EBITDA margin expanded 190 basis points to 23.7%, reflecting operating leverage from higher sales. Central America and the Andean region grew through market-share gains and traditional-channel expansion.
- Argentina Reported Strong GrowthArgentina grew 39.2%, driven by unit share gains in OTC and beverages and a favorable hyperinflation effect.
- Cash Flow IncreasedOperating cash flow rose 12.5% to MXN 496 million after a planned MXN 476 million investment in working capital. Free cash flow increased 52% to MXN 470 million from MXN 309 million a year ago, and totaled MXN 1.42 billion over the last 12 months.
- Debt Maturities Were ExtendedThe company replaced most of the MXN 1.81 billion of debt due in 2026 with long-term financing, including a 10-year amortizing term loan and a MXN 1 billion unsecured Banamex loan maturing in 2029. Short-term debt decreased 63% to MXN 1.2 billion, and 85% of gross debt was long term.
- Liquidity and Leverage Remained SoundCash and equivalents were MXN 2.76 billion, net debt was MXN 5.24 billion, and net debt was MXN 94 million lower than in the second quarter. Net debt to EBITDA was 1.4 times and debt service coverage was 5.5 times.
- Shareholder Returns ContinuedOn September 30, Genomma paid its 17th consecutive quarterly dividend of MXN 0.20 per common share, totaling almost MXN 195 million.
- Suerox Manufacturing Productivity Improved CostsThe company reduced Suerox preform costs from 1.19 pesos purchased from suppliers to 0.83 pesos manufactured internally. Antonio Zamora said current Suerox cost of goods sold was 21% lower than in 2021 after factoring in inflation and productivity initiatives.
- Innovation Pipeline and Suerox Mineral Showed Early TractionManagement said the late-June launches were accelerating growth and that five new OTC launches, Suerox Mineral, cough and cold launches, and initiatives in OTC and Tio Nacho were being deployed. Suerox Mineral generated more than 80% incremental sales in customers carrying it; the Suerox brand grew more than 80% at Walmart and more than 30% at OXXO at points during the past few months, while stores carrying Suerox Mineral reported sales three to four times higher than the old Suerox product.
- Working Capital Improvement Was ExpectedManagement committed to reducing the cash conversion cycle from 165 days to at least 140 days by the end of the fourth quarter, as winter inventory in Mexico sells through and the Argentine noncash effect normalizes.
- Commercial and Manufacturing Footprint ExpandedManagement said Genomma expanded from two U.S. customers to more than 80, from approximately 10 to 15 Latin American customers to more than 180, and built Mexico's traditional channel to almost 28% of the business. More than 68% of the business is now manufactured in Genomma's own facilities.
- Artificial Intelligence Strategy to Be PresentedAt the December 3 Investor Day in New York, the company plans to present its new operating model, future strategy, new product and formulation initiatives, and its artificial intelligence platform and agents.
MX:LABB Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 24, 2027 | 2026 (Q4) | 0.44- | 0.32 | ― | ― |
| Oct 21, 2026 | 2026 (Q3) | 0.390.51 | 0.43 | 17.78% (+0.08) | |
| Jul 23, 2026 | 2026 (Q2) | 0.470.37 | 0.35 | 5.71% (+0.02) | |
| Apr 23, 2026 | 2026 (Q1) | 0.460.49 | 0.5 | -2.00% (-0.01) | |
| Feb 26, 2026 | 2025 (Q4) | 0.390.32 | 0.47 | -31.91% (-0.15) | |
| Oct 23, 2025 | 2025 (Q3) | 0.520.43 | 0.66 | -34.39% (-0.23) | |
| Jul 23, 2025 | 2025 (Q2) | 0.530.35 | 0.63 | -44.44% (-0.28) | |
| Apr 30, 2025 | 2025 (Q1) | 0.420.50 | 0.36 | 38.89% (+0.14) | |
| Feb 27, 2025 | 2024 (Q4) | 0.580.47 | -0.11 | 527.27% (+0.58) | |
| Oct 23, 2024 | 2024 (Q3) | 0.540.66 | 0.39 | 70.10% (+0.27) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
